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Abstract
Introduction and Objectives: Dyspnea is the most common symptom among hospitalized
patients with heart failure (HF) but besides dyspnea questionnaires (which reflect the sub-
jective patient sensation and are not fully validated in HF) there are no measurable physio-
logical variables providing objective assessment of dyspnea in a setting of acute HF
patients. Studies performed in respiratory patients suggest that the measurement of electro-
myographic (EMG) activity of the respiratory muscles with surface electrodes correlates
well with dyspnea. Our aim was to test the hypothesis that respiratory muscles EMG activity
is a potential marker of dyspnea severity in acute HF patients. Methods: Prospective and
descriptive pilot study carried out in 25 adult patients admitted for acute HF. Measurements
were carried out with a cardio-respiratory portable polygraph including EMG surface elec-
trodes for measuring the activity of main (diaphragm) and accessory (scalene and pectoralis
minor) respiratory muscles. Dyspnea sensation was assessed by means of the Likert 5
questionnaire. Data were recorded during 3 min of spontaneous breathing and after breath-
ing at maximum effort for several cycles for normalizing data. An index to quantify the activ-
ity of each respiratory muscle was computed. This assessment was carried out within the
first 24 h of admission, and at day 2 and 5. Results: Dyspnea score decreased along the
three measured days. Diaphragm and scalene EMG index showed a positive and significant
direct relationship with dyspnea score (p<0.001 and p = 0.003 respectively) whereas pector-
alis minor muscle did not. Conclusion: In our pilot study, diaphragm and scalene EMG activ-
ity was associated with increasing severity of dyspnea. Surface respiratory EMG could be a
useful objective tool to improve assessment of dyspnea in acute HF patients.
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Introduction
Dyspnea is the most common symptom in patients with acute heart failure (HF) and, as such,
relief of breathlessness has been frequently employed as an end-point in clinical studies [1].
However, using dyspnea as an outcome variable has several limitations [1,2]. Indeed, there is
no validated dyspnea scale in patients with HF [3] and the use of different dyspnea question-
naires has not been standardized across studies. Moreover, previous research shows that it
may be difficult to capture a meaningful change in dyspnea with the current scales available,
which is consistent with the finding that dyspnea questionnaires are not interchangeable [4,5].
Furthermore, it is worth noting that the most frequently used dyspnea scales in HF do not take
into account the psychological aspects of dyspnea or its sensory quality [6]. As a result of the
limitations of dyspnea indices in HF, many studies focusing on dyspnea relief as end-point
have produced conflicting results [2,3]. It is noteworthy that besides dyspnea questionnaires
(which reflect the subjective patient sensation), there are no measurable physiological variables
providing objective assessment of dyspnea in a setting of acute HF patients. Therefore,
improving the tools we have to better capture the breathlessness sensation experienced by
patients with acute HF would result in better characterizing patient progress and treatment.
Given that acute HF is associated with marked breathing dysfunction caused by diaphragm
weakness [7], assessing the functional activity of respiratory muscles might provide useful
information on the degree of dyspnea severity in HF patients. Indeed, it was early reported
that HF patients had abnormally low values of maximum inspiratory pressure and impaired
diaphragm contractibility and that these diaphragm alterations correlated with dyspnea per-
ception and were associated with worse overall prognosis [8–10]. The concept that surface
electromyography (EMG) of respiratory muscles correlates with the intensity of dyspnea has
been already proved in patients with no HF but also presenting dyspnea as predominant symp-
tom: mechanical ventilation [11,12] and chronic obstructive pulmonary disease (COPD)
[13,14]. Accordingly, it is plausible to expect that similar results could be observed in HF
patients. However, whether respiratory muscles EMG is correlated with dyspnea in acute HF
patients is unknown. Thus, the aim of this study was to test the hypothesis that, in a clinical set-
ting of acute HF, surface EMG of the patient’s respiratory muscles correlates with the dyspnea
scores conventionally assessed by using a clinical scale, potentially providing a non-invasive
objective index helping to monitor patient breathlessness.
Methods
Patients
This prospective and descriptive pilot study was carried out in adult patients (>18 year old)
admitted for acute HF at the Cardiology Department of the Hospital del Mar between August
2017 and September 2018. HF diagnosis and treatment was established according to the ESC
HF Guidelines [15] and the investigation conformed to the principles outlined in the Declara-
tion of Helsinki. Patients were included within the first 24 hours of admission and after obtain-
ing their written informed consent to participate in the study, which was approved by the
Hospital del Mar Ethical Committee (number 2017/7161/I). Patients with the following condi-
tions were excluded: need for invasive or non-invasive mechanical ventilation, need for inotro-
pic drugs, pacemaker-dependent, presence of other causes of acute dyspnea (e.g.
decompensated COPD, pneumonia), metastatic active neoplasm or impossibility to give
informed consent (e.g. low level of consciousness, moderate/severe cognitive impairment, and
important language barrier).
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Protocol
Demographic and anthropometric data were collected. A first measurement was carried out
within 24 h after hospital arrival. Clinical data (blood pressure, heart rate, spontaneous breath
rate, oxygen saturation, weight) were recorded. To perform the EMG measurement, the
patient was instrumented with a cardiorespiratory portable polygraph (Sleep&Go, Sibelmed,
Spain) including nasal prongs to indirectly assess ventilation, pulse oximetry and surface
EMG. To measure the activity of the main (diaphragm) and accessory (scalene and pectoralis
minor) respiratory muscles we used 6 surface electrodes (Neuroline 715, Ambu, Copenhagen),
a pair for each muscle (Fig 1). A ground electrode (Neuroline Ground, Ambu, Copenhagen)
was placed on the right arm. All surface electrodes were placed on the patient’s right side. The
scalene electrode pair was placed in the posterior triangle of the neck between the sternocleido-
mastoid muscle and the clavicle, the pectoralis minor electrode pair was placed in the second
intercostal space, close to the sternum and the diaphragm electrode pair was placed in the sev-
enth or eighth intercostal space at the mid-clavicular line (Fig 1). After the sensors were in
Fig 1. Diagram of the measurement setting in heart failure patients. Noninvasive electromyography (EMG) of respiratory muscles was assessed by
surface electrodes. EMG signals and breathing flow indirectly sensed by a nasal cannula were recorded by a portable respiratory polygraph for
subsequent data processing.
https://doi.org/10.1371/journal.pone.0232225.g001
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place, the patient was allowed to relax and stabilize his/her breathing sensation for a few min-
utes in sitting or semi-recumbent posture and was asked about his/her dyspnea sensation by
means of the conventional Likert 5 questionnaire (score 1 = not at all short of breath, score
2 = mildly short of breath, score 3 = moderately short of breath, score 4 = severely short of
breath, score 5 = worst possible short of breath). Then, the patient was instructed not to move
or talk, and sensors data recording was started. After 3 min of spontaneous breathing the
patient was asked to breathe at maximum effort for several cycles, data recording was subse-
quently stopped, and the measurement finished after the patient was freed from the EMG elec-
trodes. The same measurement procedure was repeated along hospital admission at day 2 and
day 5 or the day of discharge, whichever came first.
EMG data processing
The clinicians performing the measurements on patients were blinded to the EMG data, which
were analyzed offline following patient discharge. The EMG signals downloaded from the
polygraph (Fig 2) were first processed to detect and remove the QRS complex. To this end, the
position of the R peak in the QRS complex was detected by using the specialized Pan-
Fig 2. Example of the EMG signals from the polygraph recorder during a normalizing breathing maneuver.
Breathing flow and EMG of diaphragm, scalene and pectoralis minor. All these signals are measured in Volts in
arbitrary scale since they correspond to an uncalibrated flow signal sensed by nasal prongs and to the muscle activity
EMG signals with an amplitude that depends on the amplifier gain. The first cycles correspond to spontaneous
breathing and the last ones (starting at time 10 s approx.) correspond to maximum effort breathing. Increase in flow
amplitude was associated with augmented respiratory muscles activity.
https://doi.org/10.1371/journal.pone.0232225.g002
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Tompkins algorithm [16], and the QRS component was removed and replaced by the vicinity
moving average values of the signal. Subsequently, the signal was rectified to compute the
mean amplitude of the EMG signal which is the most commonly used single variable to cap-
ture respiratory muscles activity in similar settings [11, 12]. Then, an index to quantify the
activity of each respiratory muscle and measurement time was computed from the amplitude
of the EMG data. This process was simultaneously applied to the EMG signals recorded in the
3 muscles, for periods including at least 3 breathing cycles during both spontaneous breathing
and maximal breathing effort. To limit the major sources of variability in the amplitude of
EMG signals -which is mainly caused by differences in the exact place of electrode position
and in the electrical impedance between the muscle and the electrode wire- we defined an
intra-measurement normalized index. To this end, the mean amplitude of EMG signal during
spontaneous breathing was divided by the mean amplitude of EMG signal during maximal
breathing effort [17]. This index was expected to be low under normal breathing conditions
(low muscle activity in spontaneous breathing as compared with high muscle activity during
maximum breathing) and increase as breathing muscles were compromised (either because
high activity during spontaneous breathing as compared with maximal breathing, or because
low amplitude during maximal effort when muscles approach fatigue). Hence, a higher EMG
index was expected as dyspnea intensity increased.
Statistical analysis
Categorical variables are presented in absolute number and percentage and were analyzed
with the Chi-Squared test. Continuous variables are expressed as mean ± standard deviation
or median and 25–75% percentiles and were analyzed using ANOVA repeated measurements
test, or Kruskal-Wallis test in case that the Shapiro-Wilk test indicated that variables were not
normally distributed. Relationship between variables was measured by the coefficient of linear
correlation. Assessment of changes in dyspnea score along days and muscle activity index as a
function of score in dyspnea was carried out by Kruskal Wallis test and ANOVA trend analy-
sis, respectively. Statistical analysis was performed with Stata/IC version 15.1. Statistical signifi-
cance was considered for p< 0.05.
Results
The study was carried out on 25 patients (44% women) who, on average, were 79 years old and
presented a mean ejection fraction of 46%, with preserved ejection fraction (EF >50%) in 45%
of them. Table 1 describes the main anthropometric and clinical patient data.
The first, second and third EMG measurements were carried out at 18 ± 5 h, 43 ± 7 h and
112 ± 22 h after admission into the Emergency Department, respectively. Table 2 shows the
evolution of clinical and analytical parameters along the whole measurement period. As
expected from patients successfully treated for an acute HF episode, we observed a decrease in
respiratory and heart rate and, at day 5, only one third of patients needed oxygen supplementa-
tion. Renal function was stable and there was a slight increase in blood sodium, reflecting good
response to treatment and decrease in volume overload. Although not measured in all patients,
NT-proBNP decreased by more than 30% reflecting good response to therapy and improved
prognosis. Consistently, dyspnea score decreased along the three measured days: from a
median 2 (1–3) in day 1 to a median 1 (1–2) in day 5 (p = 0.021). Noteworthy, respiratory rate
did not show a significant relationship with dyspnea score (p = 0.401).
Out of the total 75 possible measurements per muscle (25 patients x 3 days/patient), reliable
EMG results were obtained in 66 cases (88%) for diaphragm and pectoralis minor and in 55
cases (73%) in scalene. The activity of the scalene (but not of the pectoralis minor) as measured
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Age, years 79 ± 10
Active smoker 3 (12)
Heart failure within 12 months 8 (32)
Heart failure within 30 days 4 (29)
Ejection fraction, % 46 ± 14
Reduced LVEF (LVEF <50%) 12 (55)
Atrial fibrillation 16 (64)
Coronary artery disease 10 (40)
Moderate to severe valve heart disease 14 (56)




ACE inhibitor-ARB/MRA/ARNI 12 (48)
Mean oral furosemide dose, mg 80 ± 40
Hydrochlorothiazide 4 (16)
Data are n (%) or mean ± standard deviation. Anemia was defined as a hemoglobin < 13 g/dL in men and < 12 mg/
dL in women. Chronic kidney disease was defined as an estimated Glomerular Filtration Rate (eGFR) < 60 mL/min/
1.73m2. ACE = Angiotensin Converting Enzyme; ARB = Angiotensin Receptor Blocker; MRA = Mineralocorticoid
Receptor Antagonist; ARNI = Angiotensin Receptor Neprilysin Inhibitor.
https://doi.org/10.1371/journal.pone.0232225.t001
Table 2. Changes in clinical and analytical parameters along measurements.
Variables First measurement Second measurement Third measurement p
Routine observations
SBP, mmHg 119 ± 17 122 ± 22 117 ± 21 0.636
DBP, mmHg 65 ± 12 62 ± 14 64 ± 15 0.916
Heart rate, bpm 81 ± 17 75 ± 14 72 ± 11 0.005
Respiratory rate (RR), bpm 25 ± 6 20 ± 7 18 ± 5 <0.001
Tachypnea (RR >25 bpm) 10 (40) 4 (17) 4 (17) 0.089
Oxygen saturation, % 95 ± 3 95 ± 2 95 ± 3 0.903
Oxygen therapy 20 (80) 15 (60) 8 (32) <0.001
Blood parameters
Creatinine, mg/dL 1.27 ± 0.41 1.25 ± 0.38 1.25 ± 0.38 0.900
Urea, mg/dL 66 ± 31 75 ± 31 71 ± 24 0.255
eGFR, mL/min/1.73m2 53 ± 20 53 ± 19 53 ± 19 0.677
Sodium, mEq/L 139.9 ± 3.0 141.0 ± 3.6 141.4 ± 3.6 0.039
Potassium, mEq/L 4.14 ± 0.48 3.75 ± 0.39 4.13 ± 0.39 0.981
NT-proBNP, pg/mL� 7396 (3367–15066) 3853 (1616–8423) 3333 (1534–5038) 0.002
Data are n (%), mean ± standard deviation or median (interquartile range). SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; eGFR = estimated
Glomerular Filtration Rate.
� NT-proBNP was only measured in 12 patients at Day 2 and 19 patients at Day 5.
https://doi.org/10.1371/journal.pone.0232225.t002
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by surface EMG was significantly correlated with that of the diaphragm (r = 0.53; p< 0.001).
No significant correlation was observed between the breathing frequency and the diaphragm
EMG activity index. The scalene and particularly the diaphragm (but not the pectoralis minor)
activity measured by the EMG index showed a significant direct relationship with the clinical
dyspnea index. Indeed, the coefficients of correlation between Likert 5 and scalene and dia-
phragm EMG were 0.45 (p = 0.002; F = 9.15) and 0.48 (p< 0.001; F = 14.07), respectively. As
illustrated by Fig 3, the higher the dyspnea index the higher EMG index (p< 0.001 and
Fig 3. Diaphragm and scalene EMG activity index as a function of dyspnea (Likert 5 scale). EMG indices increased
with dyspnea severity. Data are EMG index for measurements (all patients, all days) with a given dyspnea index value.
Data are mean ± SE. See text for more details.
https://doi.org/10.1371/journal.pone.0232225.g003
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p = 0.003 respectively). By contrast, the pectoralis minor muscle did not show a significant
relationship with the clinical dyspnea scale.
Discussion
To the best of our knowledge this is the first study that has analyzed the relationship between
surface respiratory electromyography (EMG) and dyspnea in acute HF patients. This pilot
study strongly suggests that non-invasively measuring the activity of respiratory muscles is fea-
sible in the clinical setting of acute HF patients and that increased activity of diaphragm and
scalene is significantly associated with the severity of dyspnea measured by a conventional clin-
ical questionnaire.
Surface EMG has some limitations as compared with invasive EMG based on needle elec-
trodes directly sensing the muscle tissue. One limitation is that EMG signal amplitude depends
on the electrical quality of the electrode attachment on the skin. Intra-patient variability in this
interface impedance affects the EMG amplitude when repeating measurements in different
days with newly placed electrodes in a given patient. Inter-patient variability may result from
positioning the electrodes at slightly different positions and also by variation in the impedance
from the muscle to the skin, for instance because of different amount of subcutaneous fat tis-
sue. This type of intra- and inter-variability can be reduced by computing an EMG index
including an intra-measurement normalization from maximal breathing maneuvers. Another
limitation of surface EMG is that although the electrodes are placed on skin zones close to the
muscle of interest to mainly capture the electric potentials from that muscle, some signal con-
tamination by electrical activity from other muscles is possible, specifically regarding respira-
tory muscles. However, recent studies have provided validation data by comparing surface
respiratory EMG with esophageal diaphragm EMG [18] and by using surface EMG to assess
inspiratory effort [19]. Notwithstanding its limitations, surface EMG is a useful technique for
clinical purposes given its non-invasiveness.
Dyspnea is defined as “a subjective experience of breathing discomfort that consists of qual-
itatively distinct sensations that vary in intensity” [20] and is the most common symptom in
patients with acute HF. Thus, dyspnea relief has been frequently used as an end-point in clini-
cal studies [1], but limitations should be considered [1,2]. On the one hand, there is not a vali-
dated dyspnea scale in patients with HF [3]. A consensus group recommended the use of the
same instrument at baseline and repeatedly thereafter over just asking the patient whether
symptoms have changed or not [3]. On the other hand, a limitation of the use of the dyspnea
scales in HF is the lack of standardization across studies. Although a proposal to standardize
dyspnea measurement in acute HF has been published [3], studies in acute HF use different
scales at different time points and how dyspnea was measured is frequently not described.
Some studies assess dyspnea as early as within 1 hour of first medical evaluation [21] whereas
others could include patients within 48 hours of hospitalization [22]. Our first measurement
was carried out at 18 ± 5 h from admission into the Emergency Department, therefore captur-
ing the worst possible clinical scenario. Interestingly, the severity of dyspnea according to the
dyspnea scale was not severe (a median of 2 with Likert 5 scale (i.e. mildly short of breath)
even in the most acute phase. However, all patients were in need of oxygen therapy and respi-
ratory rate was high (Table 2). These baseline characteristics were similar to other studies in
acute HF [4]. In previous reports, only very severely baseline dyspnea was associated with dys-
pnea improvement by 5-point Likert Scale whereas moderately and severe dyspnea were not.
In contrast, baseline dyspnea was associated with dyspnea improvement by Visual Analog
Scale [4]. These data show that the most frequently used dyspnea scales are not interchange-
able. Furthermore, not all scales have an established minimal clinically important difference
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[23] and it may be difficult to capture a meaningful change in dyspnea with the current scales
available [4,5]. Finally, psychological and emotional distress has been significantly associated
with dyspnea in HF [24,25] but these components or alterations of sensorial quality are usually
nor assessed in the most commonly scales used for dyspnea assessment [6]. Accordingly, it is
not surprising that many HF drug studies that have dyspnea relief as end points have failed to
show a difference between the active drug and placebo. Whether they reflect a real lack of effect
of the medication tested or the use of a suboptimal tool to assess the endpoint is unclear. Given
the shortcomings of common dyspnea scales and their subjective nature, from a clinical point
of view it would be useful to have an objective index that would bring additional information
about dyspnea.
Since acute HF is associated with marked inspiratory dysfunction [7–10], we hypothesized
that assessing the activity of respiratory muscles could provide a useful index associated with
dyspnea in these patients. In addition to the diaphragm, which is the main inspiratory muscle,
we also focused on accessory respiratory muscles since they are recruited in healthy subjects
under conditions more strenuous than spontaneous breathing at rest [26,27] as well as in
patients with respiratory diseases presenting dyspnea as a prominent symptom. For example,
in patients with COPD, a disease frequently associated with dyspnea both in the stable and
acute phase, surface inspiratory electromyograms (EMG) of respiratory muscles have been
correlated with the intensity of dyspnea and prognosis [13,14]. Even when treatment with sal-
meterol-fluticasone in severe COPD was not associated with significant change in hyperinfla-
tion or pulmonary mechanics, this treatment induced a significant decrease in activity of the
chest wall parasternal inspiratory muscle [28], suggesting that EMG could be a sensitive mea-
sure to monitor improvement in these respiratory patients. Surface EMG also correlated with
breathlessness in patients with cystic fibrosis during exercise [29]. Another example showing a
relationship between dyspnea and respiratory muscles activity is mechanical ventilation. In
this setting, a strong correlation between accessory respiratory EMG activity and the severity
of dyspnea was described in patients subjected to invasive pressure support ventilation [11]. It
has also been reported that scalene EMG activity level was correlated with dyspnea intensity in
subjects under non-invasive mechanical ventilation [12,30]. The results obtained in the present
study indicate that respiratory muscles EMG correlate with dyspnea not only in patients in
whom breathlessness is induced by a respiratory system disease, but also in acute HF, a situa-
tion where the main cause of dyspnea is not a respiratory disorder. In particular, in our HF
patients we observed a correlation between diaphragm and scalene EMGs, the two respiratory
muscles that showed significant correlation with dyspnea (Fig 3). Interestingly, the lack of cor-
relation observed between respiratory frequency and diaphragm EMG is consistent with our
finding that breathing frequency did not depend on dyspnea score and with the fact that the
breathing rate has not been previously reported as a good index to assess dyspnea.
Dyspnea, a subjective sensation experienced by patients with acute HF, is determined by
both physical and psychological components which are still poorly understood. Although
alteration of breathing activity is clearly accompanying the dyspneic events in HF patients, we
did not expect that surface EMG of respiratory muscles provided a full assessment of dyspnea.
However, the correlation we found between Likert 5 scale and diaphragm activity suggests that
surface EMG could play a role as an objective tool helping to better assess dyspnea in acute
HF. Interestingly, the measurement of surface EMG provided a feasible parameter with up to
88% technically correct measures overall. Notwithstanding the fact that we carried out single
measurements, estimation of the EMG index could be carried out repeatedly and sequentially
at different time intervals to both increase estimation robustness and provide time course
monitoring. In this connection, future clinical applications could be developed for automati-
cally monitoring patient’s dyspnea, in particular at the patient’s home (with potential
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telemetric follow-up). In fact, small, portable and relatively cheap recorders including surface
EMG are currently available for home monitoring sleep apnea, and new miniaturized and
wireless EMG devices are being developed [31–33].
This proof of concept pilot study has some limitations. It only included patients with
breathlessness at inclusion but many patients with acute HF are comfortable at rest but breath-
less on slight exertion. However, these patients, who can account for as much as 56% of acute
HF patients, have usually also been excluded from clinical trials [34], especially those with dys-
pnea improvement as an end-point. Given our small sample size, we did not attempt to assess
whether EMG values can be associated with prognosis. Moreover, dyspnea was assessed by
one of the most common clinical questionnaires (Likert 5). As it has been described that other
usual clinical indices (such as Visual Analog Scale) are not interchangeable to assess acute HF,
future studies should assess whether surface respiratory EMG captures dyspnea as compared
with other clinical indices of dyspnea. The results from this pilot study also suggest to further
investigating the correlation between dyspnea severity and diaphragm EMG index over time
adjusting for the change in NT-pro BNP and other biomarkers. Such a mechanistic research
would allow to unravel the physiological signal captured by the EMG index and to ascertain
whether diaphragm involvement in HF failure is a mere consequence of hypoperfusion and/or
volume overload or is mediated by HF-related proinflammatory cytokines upregulation
thereby independently contributing to dyspnea in these patients. This mechanistic informa-
tion would help to optimally target the patient phenotype and clinical status for potential clini-
cal application of surface EMG to assess dyspnea in HF.
Conclusions
Non-invasive measurement of respiratory muscles EMG is feasible in the setting of acute HF
patients. Diaphragm, and less strongly scalene, EMG index showed a significant direct rela-
tionship with Likert 5 dyspnea scale. The results in this study provide a proof of concept that
surface EMG index could be used as a marker of breathlessness severity and employed as a
more objective end-point in acute HF trials in clinical settings as well as a potential home mon-
itoring tool in HF patients at risk. However, more research and future clinical trials are
required to substantiate the novel results obtained in this pilot study.
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